Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

10.79 -0.05 (-0.46%)
Streaming Delayed Price Updated: 11:10 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. 
Via Benzinga
News headline image
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T. 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T. 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness ↗
Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year. 
Via Benzinga
News headline image
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket ↗
Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European... 
Via Benzinga
News headline image
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
News headline image
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022 ↗
  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
91 Biggest Movers From Friday ↗
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
News headline image
Looking Into 4D Molecular Therapeutics's Return On Capital Employed ↗
Benzinga Pro data, 4D Molecular Therapeutics (NASDAQ:FDMT) reported Q4 sales of $92.00 thousand. Earnings fell to a loss of $25.08 million, resulting in a 12.79% decrease from last quarter. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
4D Molecular Shares Updated Data From Fabry Disease Trial ↗
4D Molecular Therapeutics Inc (NASDAQ: FDMT) has posted updated interim data from the Phase 1/2 trial of 4D-310 in Fabry disease at the 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
News headline image
6 Underperforming IPO Stocks To Buy On The Dip ↗
Here are six 2021 IPO stocks to buy on the dip, according to Bank of America. 
Via Talk Markets
News headline image
6 Underperforming IPO Stocks To Buy On The Dip ↗
The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Gold Down 1%; A10 Networks Shares Gain Following Q3 Results ↗
Toward the end of trading Friday, the Dow traded down 0.03% to 35,721.05 while the NASDAQ fell 0.07% to 15,437.03. The S&P also fell, dropping 0.08% to 4,592.96. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022 ↗
Upgrades According to Vertical Research, the prior rating for Livent Corp (NYSE: 
Via Benzinga
News headline image
66 Biggest Movers From Friday ↗
Gainers Bakkt Holdings, Inc. (NASDAQ: BKKT) shares surged 66.1% to close at $42.52 on Friday on continued volatility after the company recently announced partnerships with... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.